雷珠单抗治疗新生血管性眼病的临床疗效观察

Clinical effect of intravitreal ranibizumabin in the treatment of ocular neovascular disease

目的探讨玻璃体腔注射雷珠单抗(商品名Lucentis)治疗新生血管性眼病的临床疗效、安全性和适应证。方法选取临床确诊为新生血管性眼病患者44例(45眼),患眼接受玻璃体腔注射雷珠单抗0.5 mg/0.05 ml,随访6个月,观察治疗前和治疗后的最佳矫正视力(BCVA)、光学相干断层扫描(OCT)及眼压等变化情况。结果 28眼治疗后第1、2、3、6月平均BCVA较治疗前均有明显提高,差异有统计学意义(P<0.01)。除新生血管性青光眼,其他各组患眼治疗后CMT均有不同程度下降。随访期间未发现与治疗相关的全身及眼部并发症。结论玻璃体腔注射雷珠单抗在短期内使脉络膜新生血管萎缩、减轻视网膜水肿,提高患眼视力。在规范操作下进行球内注射雷珠单抗是相对安全的。

Objective To evaluate the clinical efficacy,safety and indications of intravitreal injections of ranibizumab in the treatment of ocular neovascular disease.Methods In this prospective study,44 patients （45 eyes） diagnosed as ocular neovascular disease were treated with intravitreal Lucentis 0.05 mg/0.05 ml.The patients were followed up for 6 months.The change of BCVA, OCT and IOP before and after treatment were observed.Results Compared to baseline,average BCVA of 28 eyes were significantly im-proved after 1,2,3 and 6 month of treatment （P〈0.01）.In addition to neovascular glaucoma,the CMT in other groups was also de-creased to varying degrees.There were no systemic or ocular serious side effects during the follow-up.Conclusion For ocular neovas-cular disease,intravitreal ranibizumab could control CNV progress,reduce retina edema and improve vision acuity in a short-term.With standardized operation,the intravitreal injection of ranibizumab is relatively safe.